Market Movers

Palantir Technologies Inc. (PLTR)

209.05 USD +10.27 (+5.17%) Volume: 37.37M

Palantir Technologies Inc.’s stock price soars to 209.05 USD, marking a positive trading session with a hefty increase of +5.17% and a trading volume of 37.37M, encapsulating its impressive YTD performance with a surge of +17.61%.

Latest developments on Palantir Technologies Inc.

Palantir Technologies stock has hit an all-time high as Wall Street grows bullish on the next phase of growth for the company. With recent upgrades from Goldman Sachs and Barclays, the software giant is seeing increased momentum and investor interest. Palantir’s focus on sovereign AI and government contracts, as well as its strong financial performance, have contributed to the stock’s rise. Despite some skepticism in the past, analysts are now turning bullish on Palantir, predicting further upside potential and a bright future ahead.

Palantir Technologies Inc. on Smartkarma

Analysts on Smartkarma are closely following Palantir Technologies, with contrasting views on the company’s future. Baptista Research, in their report titled “Palantir Technologies’ 93% Revenue Surge — Is The AI Growth Engine Still Accelerating?”, leans bullish on the company’s performance, highlighting a 93% year-over-year revenue growth in the second quarter of fiscal 2026. On the other hand, William Keating, in his report “Palantir CEO Alex Karp Declares War On Anthropic, OpenAI”, takes a bearish stance, focusing on concerns related to data caching and intellectual property theft in the AI space.

αSK Primers also provide a bullish outlook in their report “Primer: Palantir Technologies (PLTR US) – Jul 2026″, emphasizing Palantir’s hyper-growth driven by its position in the U.S. government sector and the commercial market. Another report by Baptista Research, titled “Palantir Technologies: The $7.656 Billion Outlook Raises The Growth Durability Bar!”, further supports the bullish sentiment, highlighting strong revenue growth and momentum in both commercial and government markets for Palantir Technologies.

A look at Palantir Technologies Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Palantir Technologies, a company that develops software for data analysis, has received high scores in Growth, Resilience, and Momentum according to Smartkarma Smart Scores. This indicates a positive long-term outlook for the company in terms of its ability to expand, adapt to challenges, and maintain a strong upward trend. While its scores in Value and Dividend are lower, the strong performance in key areas suggests that Palantir Technologies may still be a promising investment for those looking for growth potential.

With a focus on developing software to analyze various types of data, Palantir Technologies has positioned itself as a key player in the industry. Its high scores in Growth, Resilience, and Momentum reflect its strong market position and potential for continued success. Despite lower scores in Value and Dividend, the company’s overall outlook remains positive, making it a company to watch for investors interested in companies with strong growth prospects.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Moderna, Inc. (MRNA)

225.00 USD +28.00 (+14.21%) Volume: 28.83M

Moderna, Inc.’s stock price soars to $225.00, marking a significant trading session increase of +14.21% and an astounding YTD growth of +662.97%, driven by a robust trading volume of 28.83M, solidifying MRNA’s dominant market position.

Latest developments on Moderna, Inc.

Moderna’s stock price surged today after reports of a planned national cancer vaccine effort, leading to a 14% gain and setting a fresh 52-week high. The company’s inclusion in the Nasdaq-100 index also contributed to the stock’s rise, with investors optimistic about the potential impact of the COO appointment. Moderna’s collaboration with Tempus and Merck on cancer vaccine initiatives further fueled the stock’s momentum, as did the announcement of a multi-year partnership with Everest Medicines to accelerate mRNA clinical pipeline. With ongoing developments in the oncology sector and a bullish outlook on the company’s future, Moderna continues to attract attention from investors and analysts alike.

Moderna, Inc. on Smartkarma

Analysts on Smartkarma, like Anjana Amarasuriya and Baptista Research, have been covering Moderna closely. Anjana Amarasuriya‘s insights indicate that Moderna is expected to make significant changes at the December 2026 index rebal event, with an estimated one-way flow of around US$42bn. Additionally, Baptista Research highlights Moderna’s breakthrough in cancer vaccines, particularly its positive results in the Phase 3 INTerpath-001 melanoma study. This success has propelled Moderna into a new phase of its post-pandemic story, generating optimism among investors.

Furthermore, Baptista Research also notes Moderna’s progress in developing a flu vaccine, which adds another catalyst beyond COVID. The company’s financial results for the second quarter of 2026 showed promising revenue generation, with a strategic shift towards international markets. Meanwhile, αSK Primers provide a comprehensive overview of Moderna’s transition from its pandemic-era success with the Spikevax COVID-19 vaccine to a broader mRNA-based platform. Despite facing challenges in declining COVID-related revenue, Moderna’s future value hinges on the success of its late-stage pipeline and innovative products like the RSV vaccine and personalized cancer vaccine.

A look at Moderna, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, Moderna has a positive long-term outlook. With a strong momentum score of 5, the company is showing promising growth potential. Additionally, Moderna has a resilience score of 3, indicating its ability to withstand market challenges. While the value and dividend scores are not as high, the growth and momentum scores suggest that Moderna is well-positioned for future success in the biotechnology industry.

Moderna, Inc. focuses on developing messenger RNA therapeutics and vaccines for various diseases. The company’s emphasis on infectious, immuno-oncology, and cardiovascular diseases highlights its commitment to addressing significant health challenges. With favorable Smartkarma Smart Scores in growth and momentum, Moderna appears to be on a path towards continued innovation and advancement in the biotechnology sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Crown Castle Inc. (CCI)

79.64 USD +10.75 (+15.60%) Volume: 14.17M

Crown Castle Inc.’s stock price shows a promising surge of +15.60% this trading session, currently standing at 79.64 USD with a robust trading volume of 14.17M. However, the year-to-date performance indicates a decline of -10.39%, highlighting the volatile nature of CCI’s stock price.

Latest developments on Crown Castle Inc.

Crown Castle Intl (CCI) stock price has been influenced by recent developments, including the bond profiles of CCI4490185 and US22822VAT89. Investors are closely monitoring the coupon rates and redemption details of these bonds, as they can impact the company’s financial health. These factors, along with market trends and investor sentiment, have contributed to the fluctuations in Crown Castle Intl‘s stock price today. Stay updated on CCI’s news and history to make informed investment decisions.

Crown Castle Inc. on Smartkarma

Analyst Jacob Cheng from Smartkarma recently published a bearish research report on Crown Castle Intl titled “The US 5G Capex Cliff: Crown Castle’s Structural Churn and Yield Compression.” In the report, Cheng highlighted how US carriers cutting network infrastructure spending has exposed Crown Castle to significant organic revenue headwinds and valuation multiple compression compared to its internationally diversified peers. The company is facing challenges such as legacy Sprint consolidations and the DISH Wireless fallout, which are expected to result in a substantial revenue decrease of 240 million USD in 2026, impacting its domestic growth trajectory. Additionally, a costly fiber divestment led to a dividend cut to 4.25 USD, revealing persistent coverage weaknesses despite efforts to reduce debt and reset the corporate strategy.

A look at Crown Castle Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Crown Castle Intl has a strong outlook for dividends, resilience, and growth. With a top score in dividends, investors can expect consistent and reliable payouts from the company. Additionally, its high resilience score indicates that Crown Castle Intl is well-positioned to weather economic downturns and market volatility. While the growth score is not as high, it still suggests potential for expansion and development in the future. Overall, Crown Castle Intl‘s Smart Scores point to a promising long-term outlook for investors.

Crown Castle International Corp. operates as a real estate investment trust, owning and leasing infrastructure for wireless communications. With a strong focus on providing wireless communication coverage in the United States and Australia, the company plays a crucial role in supporting the telecommunications industry. Smartkarma Smart Scores highlight Crown Castle Intl‘s strengths in dividends, resilience, and growth, indicating a positive outlook for the company’s future performance and stability in the market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Humana Inc. (HUM)

431.87 USD +44.75 (+11.56%) Volume: 4.99M

Humana Inc.’s stock price has experienced a significant rise, currently trading at 431.87 USD, reflecting a robust surge of +11.56% in the latest trading session. With a trading volume of 4.99M shares, the healthcare company has exhibited a remarkable YTD increase of +68.61%, demonstrating its strong market performance.

Latest developments on Humana Inc.

Humana Inc. stock prices surged today after the health insurer topped the 2027 Medicare star ratings, leading to a significant improvement in its Medicare Advantage ratings. The company’s shares jumped 12% following the news, with 95% of its Medicare Advantage members now in 4-star plans for 2027. This positive development sparked bullish repricing, causing the stock to hit a 52-week high. Analysts are optimistic about Humana’s Medicare Advantage prospects, with upgrades and bullish calls from top firms like Baird and Barclays. The company’s strong performance in Medicare Advantage ratings has positioned it as a leader in the managed care sector, outperforming competitors and affirming its full-year adjusted earnings outlook for 2026.

Humana Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma have provided bullish insights on Humana Inc, highlighting the company’s strategic initiatives and financial performance. In their report titled “Humana’s 600,000-Member Reset — Can It Restore 3% Medicare Advantage Margins?”, they note that Humana Inc. has been maintaining positive momentum in key operational and financial metrics. The company’s focus on enhancing product and customer experience, advancing clinical excellence, and optimizing capital allocation, particularly in growth areas like Medicaid and its CenterWell platform, has supported its membership growth and growth ambitions.

In another report by Baptista Research on Smartkarma, analysts continue to express bullish sentiment towards Humana Inc. in their report “Humana’s CenterWell Expansion Could Reshape Its Long-Term Care Delivery Model!”. The analysts acknowledge the company’s stable start to 2026 and its commitment to returning to a sustainable Medicare Advantage margin of at least 3% by 2028. With a focus on managing growth dynamics and membership retention, Humana Inc. aims to address the gap between medical cost trends and program funding while reshaping its long-term care delivery model through initiatives like the expansion of its CenterWell platform.

A look at Humana Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Humana Inc. is positioned well for the long-term future based on the Smartkarma Smart Scores. With a high score in Value and Momentum, the company is seen as having strong potential for growth and stability. The Value score indicates that the company is trading at an attractive price relative to its fundamentals, while the Momentum score suggests that Humana is experiencing positive trends in stock price. These factors bode well for the company’s outlook in the coming years.

Although Humana Inc. may not score as high in Growth and Dividend, its Resilience score of 3 indicates that the company is able to weather economic downturns and challenges. This, coupled with its strong Value and Momentum scores, suggests that Humana is a solid investment option for those looking for long-term growth and stability in the managed health care sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Biggest stock gainers today in S&P 500

Biggest stock losers today in S&P 500

What is Smartkarma SmartScore?

It is a compound score for a Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores (Value, Dividend, Growth, Resilience, Momentum scores) computed by Smartkarma.

The best stock screener – Smartkarma SmartScore Screener

Smartkarma’s stock screener, Smartkarma SmartScore Screener, allows you to easily discover undervalued gems, high dividend stocks, and high growth stocks, across multiple countries and sectors.

Explore the Smartkarma SmartScore Screener now.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Biggest stock gainers today in Hong Kong

Biggest stock losers today in Hong Kong

What is Smartkarma SmartScore?

It is a compound score for a Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores (Value, Dividend, Growth, Resilience, Momentum scores) computed by Smartkarma.

The best stock screener – Smartkarma SmartScore Screener

Smartkarma’s stock screener, Smartkarma SmartScore Screener, allows you to easily discover undervalued gems, high dividend stocks, and high growth stocks, across multiple countries and sectors.

Explore the Smartkarma SmartScore Screener now.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Xiaomi (1810)

25.96 HKD +2.30 (+9.72%) Volume: 255.61M

Xiaomi’s stock price surged by +9.72% to 25.96 HKD in the recent trading session, with a robust trading volume of 255.61M, signaling a potential recovery despite a year-to-date percentage change of -33.94%.

Latest developments on Xiaomi

Xiaomi‘s stock price surged today by 9% following the news that their Skynomad series has garnered an impressive 70,000 firm orders in its first month. This positive development in their electric vehicle (EV) sector has boosted investor sentiment significantly. Additionally, Xiaomi‘s HyperOS 4, which now supports seamless sync of photos, messages, and files with iPhone devices, has also contributed to the company’s upward trajectory. Talks with Nio over a potential Munich hub and the leak of the Xiaomi Redmi Turbo 6 Max with a massive battery and 2K display have further fueled excitement around Xiaomi‘s future prospects.

Xiaomi on Smartkarma

Analysts on Smartkarma, such as Henry Soediarko, have been covering Xiaomi closely. In a recent report titled “Xiaomi (1810): Large CapEx,” Soediarko expressed a bearish sentiment on the company. The report highlighted Xiaomi‘s Q1 2026 results, which showed a decline in revenue and net income due to higher DRAM prices. Despite management’s efforts to launch a share buyback, the negative trend may not be easily reversed. The planned large CapEx for Xiaomi‘s phase 2 EV megafactory, AI infrastructure, and other projects could further deplete its cash reserves.

A look at Xiaomi Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Xiaomi seems to have a promising long-term outlook. With high scores in value, growth, resilience, and momentum, the company appears to be well-positioned for success in the consumer electronics and technology industry. Xiaomi‘s focus on innovation and a wide range of products, including smartphones and AIoT devices, could contribute to its continued growth and competitiveness in the market.

Although Xiaomi‘s dividend score is lower, the overall positive ratings in other key factors suggest that the company has strong potential for future expansion and profitability. As a Chinese multinational corporation with a diverse portfolio of products and internet services, Xiaomi‘s strategic approach to technology and consumer needs could drive its success in the coming years.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Wuxi Biologics (Cayman) (2269)

53.85 HKD -0.25 (-0.46%) Volume: 138.21M

Wuxi Biologics (Cayman)’s stock price stands at 53.85 HKD, experiencing a slight dip of -0.46% this trading session with a trading volume of 138.21M, yet boasting a substantial YTD percentage change of +71.28%, highlighting its impressive performance in the stock market.

Latest developments on Wuxi Biologics (Cayman)

Wuxi Biologics has been making significant strides in the biomanufacturing industry, with recent events leading to fluctuations in its stock price. The company showcased its commitment to empowering biomanufacturing in Europe at CPHI Milan 2026, while also breaking ground on a CRDMO center in Singapore. Furthermore, Wuxi Biologics saw success in passing an FDA inspection, which positively impacted its investment story and contributed to its stock nearing a yearly high. Despite a slight dip in stock price on October 8, 2026, Wuxi Biologics continues to trade near its 52-week high following strong growth in the first half of the year. The overall surge in the biotech and pharma sector has also played a role in Hong Kong stocks extending gains, with Zhipu jumping over 7%.

Wuxi Biologics (Cayman) on Smartkarma

Analysts on Smartkarma have recently provided coverage on Wuxi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO). Nicholas Tan, in his bearish analysis, discussed the company’s plan to raise US$500m through a partial selldown of its stake in Wuxi Biologics, highlighting a streak of underperforming deals. On the other hand, Tina Banerjee’s bullish outlook emphasized the company’s accelerated growth driven by integrated projects, resulting in a raised revenue guidance for 2026. This contrasting sentiment reflects the diverse perspectives of independent analysts on the platform.

Ke Yan, CFA, FRM, and αSK Primers also contributed their insights on Wuxi Biologics, with Ke Yan forecasting the company’s potential inclusion in the HSCEI Index rebalance and αSK Primers providing a detailed primer on the company’s business model and growth drivers. The coverage on Smartkarma offers investors a comprehensive view of Wuxi Biologics, incorporating both bullish and bearish perspectives to aid in making informed investment decisions.

A look at Wuxi Biologics (Cayman) Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the long-term outlook for Wuxi Biologics, the company seems to have a promising future based on the Smartkarma Smart Scores. With a high score in Growth and Momentum, Wuxi Biologics is positioned well for expansion and continued success in the biologics industry. Additionally, the company’s strong Resilience score indicates its ability to weather challenges and adapt to market changes, further solidifying its potential for long-term growth.

Although Wuxi Biologics scores lower in the Dividend category, its overall outlook remains positive with a balanced combination of Value, Growth, Resilience, and Momentum. As a global Contract Research, Development, and Manufacturing Organization specializing in biologics, Wuxi Biologics offers end-to-end solutions for various complex modalities. With its comprehensive services and strong presence in the industry since its founding in 2010, Wuxi Biologics is well-positioned to continue its success in the biologics discovery, development, and manufacturing sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

Horizon Robotics (9660)

4.12 HKD +0.17 (+4.18%) Volume: 96.26M

Horizon Robotics’s stock price sees a boost, closing at 4.12 HKD with a gain of +4.18% this trading session, backed by a robust trading volume of 96.26M. However, the stock continues to reflect a downtrend YTD with a percentage change of -52.48%.

Latest developments on Horizon Robotics

Horizon Robotics (SEHK:9660) is facing fresh scrutiny today as investors react to the company’s recent financial performance. With increasing losses and rising research and development costs, shareholders are questioning the true value of the company. The stock price of Horizon Robotics (8YO.HM) has dipped to 4.00 HKD, marking a 1.11% decline in value. This decline comes as analysts conduct an in-depth analysis of the company’s market performance. Despite efforts to extend their task horizon through innovations like humanoid technology, Horizon Robotics is facing challenges that are impacting their stock price today.

A look at Horizon Robotics Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Horizon Robotics, a company based in Beijing, China, focuses on developing AI chips and software platforms for intelligent vehicles like self-driving cars and ADAS. With a Smart Score of 5 for Momentum, the company shows strong potential for future growth and development in the AI industry. This high score indicates that Horizon Robotics is making significant strides in the market, positioning itself as a key player in the field of artificial intelligence.

Although Horizon Robotics scores lower in areas like Dividend and Value, with scores of 1 and 3 respectively, the company demonstrates resilience with a score of 3. This resilience factor suggests that Horizon Robotics is able to adapt and withstand challenges in the industry, ensuring its long-term sustainability. With a balanced mix of growth potential and stability, Horizon Robotics appears to have a promising outlook in the evolving landscape of AI technology.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma

China Construction Bank (939)

9.73 HKD +0.07 (+0.72%) Volume: 172.13M

China Construction Bank’s stock price stands strong at 9.73 HKD, marking a positive trading session with a +0.72% increase, backed by a hefty trading volume of 172.13M, and an impressive YTD percentage change of +26.59%, demonstrating the bank’s robust financial performance and investment attractiveness.

Latest developments on China Construction Bank

China Construction Bank stock has been relatively stable in pre-market trading at EUR 1.10, with no change in value. Recent events such as QatarEnergy securing a $3 billion loan from Chinese banks and the Export-Import Bank of China opening its first office in Chile have influenced market sentiment. Additionally, China Construction Bank raised fresh AT1 capital amidst an undervalued view, while also raising CNY 40 billion. Despite some fluctuations, the stock has held near its 52-week high, showing resilience in the face of external factors like mortgage risk flagged by Risk.net. These developments have contributed to the stock’s movements, with after-hours trading showing a slight decrease to EUR 1.08, but a subsequent increase in pre-market trading to EUR 1.09, up by 0.00 percent.

China Construction Bank on Smartkarma

Analysts on Smartkarma have varying opinions on China Construction Bank (CCB). According to a report by αSK Primers, the bank benefits from a dominant market position and government backing as one of China’s ‘Big Four’ state-owned banks. Despite facing challenges from a challenging macroeconomic environment, including a property sector downturn and moderating growth, CCB offers attractive valuation and dividend yield, making it appealing to income-oriented investors.

On the other hand, analyst Nico Rosti has a bearish view on China Construction Bank H (939 HK), noting that the stock is currently ultra-overbought and facing passive selling flows at the end of May. Rosti suggests that investors may consider selling now to navigate the expected passive selling ahead of the May rebalance. This contrasting sentiment highlights the diverse perspectives among analysts covering CCB on Smartkarma.

A look at China Construction Bank Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

China Construction Bank, a leading commercial bank in China, has been rated highly in various aspects according to Smartkarma Smart Scores. With a strong score in Value, Dividend, Resilience, and Momentum, the bank seems to be in a favorable position for long-term growth and stability. Although its Growth score is slightly lower, the overall outlook for China Construction Bank appears promising.

As a key player in the financial sector, China Construction Bank offers a wide range of services including personal and corporate banking, wealth management, and treasury operations. With a solid foundation in infrastructure loans, residential mortgages, and fund management, the bank has established itself as a reliable institution since its founding in 1954. With high scores in Value, Dividend, Resilience, and Momentum, China Construction Bank is well-positioned to continue its success in the future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma